Chimeric antigen receptor containing a toll-like receptor intracellular domain
AssigneeShenzhen In Vivo Biomedicine Technology Limited Company
InventorsPeng Li, Yunxin Lai, Simiao Lin, Yao Yao
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
Claims13
A chimeric antigen receptor, comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and an intracellular domain, wherein, the intracellular domain contains at least:
- a Toll-like receptor 1 intracellular signaling domain with the nucleotide sequence of SEQ ID NO. 11 and/or a Toll-like receptor 2 intracellular signaling domain with the nucleotide sequence of SEQ ID NO. 12, a CD3ζ intracellular signaling domain, and a CD28 intracellular signaling domain, wherein the antigen is a tumor associated antigen.
Dependencies are inferred from the claim text.